Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis

被引:113
作者
Fainardi, E
Castellazzi, M
Bellini, T
Manfrinato, MC
Baldi, E
Casetta, I
Paolino, E
Granieri, E
Dallocchio, F
机构
[1] Univ Ferrara, Arcispedale S Anna, Dept Neurol, Multiple Sclerosis Ctr,Sect Neurol, I-44100 Ferrara, Italy
[2] Arcispedale St Anna, Azienda Osped Univ, Dept Neurosci, Neuroradiol Sect, I-44100 Ferrara, Italy
[3] Univ Ferrara, Dept Biochem, I-44100 Ferrara, Italy
关键词
cerebrospinal fluid; intrathecal synthesis; multiple sclerosis; MMP-9; TIMP-1;
D O I
10.1191/135248506ms1274oa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In this study, we employed a sensitive activity assay system to measure cerebrospinal fluid (CSF) and serum levels of active matrix metalloproteinase-9 (MMP-9) in 37 relapsing-remitting (RR), 15 secondary progressive (SP) and nine primary progressive ( PP) multiple sclerosis (MS) patients, grouped according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also studied, as neurological controls, 48 patients with other inflammatory neurological disorders (OIND) and 48 with non-inflammatory neurological disorders (NIND). To assess active MMP-9/TIMP-1 circuit, CSF and serum levels of MMP-9 tissue inhibitor TIMP-1 were quantified by ELISA in the same patient population. CSF mean levels of active MMP-9, CSF active MMP-9/TIMP-1 ratios and intrathecal active MMP-9 synthesis, as indicated by specific index, were more elevated in MS than in NIND (P < 0.05, < 0.02 and < 0.02, respectively), serum active MMP-9/TIMP-1 ratio was higher in MS (P < 0.01) and OIND (P < 0.02) than in NIND, and serum TIMP-1 concentrations were lower in MS than in NIND (P < 0.05). More importantly, serum active MMP-9 mean levels, serum active MMP-9/TIMP-1 ratio and intrathecal production of active MMP-9 were increased in MS patients with clinical (P < 0.001, < 0.001 and < 0.05, respectively) and MRI (P < 0.001, < 0.001 and < 0.02, respectively) disease activity, whereas CSF mean concentrations of active MMP-9 and CSF active MMP-9/TIMP-1 ratio were enhanced only in MS patients with MRI evidence of disease activity (P < 0.02 and < 0.01, respectively). Altogether, these findings suggest that a shift in MMP-9/TIMP-1 balance towards proteolytic activity of MMP-9 could be relevant in MS immune dysregulation. In addition, our results indicate that CSF and serum levels of active MMP-9 may represent a potential surrogate biomarker for monitoring MS disease activity. In particular, serum active MMP-9/TIMP-1 ratio seems to be a very appropriate indicator of ongoing MS inflammation, since it is easily measurable.
引用
收藏
页码:294 / 301
页数:8
相关论文
共 31 条
[1]   Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes [J].
Avolio, C ;
Ruggieri, M ;
Giuliani, F ;
Liuzzi, GM ;
Leante, R ;
Riccio, P ;
Livrea, P ;
Trojano, M .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 136 (1-2) :46-53
[2]   Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis [J].
Bar-Or, A ;
Nuttall, RK ;
Duddy, M ;
Alter, A ;
Kim, HJ ;
Ifergan, I ;
Pennington, CJ ;
Bourgoin, P ;
Edwards, DR ;
Yong, VW .
BRAIN, 2003, 126 :2738-2749
[3]   Development of biomarkers in multiple sclerosis [J].
Bielekova, B ;
Martin, R .
BRAIN, 2004, 127 :1463-1478
[4]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231
[5]   Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS [J].
Correale, J ;
Molinas, MDB .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 140 (1-2) :198-209
[6]   Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients [J].
Galboiz, Y ;
Shapiro, S ;
Lahat, N ;
Rawashdeh, H ;
Miller, A .
ANNALS OF NEUROLOGY, 2001, 50 (04) :443-451
[7]   GELATINASE IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS AND OTHER INFLAMMATORY NEUROLOGICAL DISORDERS [J].
GIJBELS, K ;
MASURE, S ;
CARTON, H ;
OPDENAKKER, G .
JOURNAL OF NEUROIMMUNOLOGY, 1992, 41 (01) :29-34
[8]   Matrix metalloproteinases in inflammatory demyelination - Targets for treatment [J].
Kieseier, BC ;
Seifert, T ;
Giovannoni, G ;
Hartung, HP .
NEUROLOGY, 1999, 53 (01) :20-25
[9]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[10]   Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis - A longitudinal clinical and MRI study [J].
Lee, MA ;
Palace, J ;
Stabler, G ;
Ford, J ;
Gearing, A ;
Miller, K .
BRAIN, 1999, 122 :191-197